Latest News and Press Releases
Want to stay updated on the latest news?
-
Napco (NSSC) Under Scrutiny: Investor Suit and Sales Slump Shake Investor Confidence – Hagens Berman
SAN FRANCISCO, June 15, 2025 (GLOBE NEWSWIRE) -- Shares in Napco Security Technologies, Inc. (NASDAQ: NSSC) are trading down nearly 21% year-to-date, as the security technology company continues to...
-
SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Investors in Abacus Global Management, Inc. (NASDAQ: ABL) experienced another substantial decline in share price today following the release of a...
-
SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- A year ago, Bay Area biotech firm Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) was riding high on the promise of its newly approved cell therapy,...
-
SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Cockrell v. UroGen Pharma Ltd. et al., No. 3:25-cv-06088 (D. N.J.) has been filed and seeks to represent...
-
SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Compass Diversified’s (NYSE: CODI) tumultuous spring continued as Jefferies analysts recently downgraded the company’s stock amid a sweeping...
-
SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Shares in Napco Security Technologies, Inc. (NASDAQ: NSSC) are trading down nearly 21% year-to-date, as the security technology company continues to...
-
SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.) has been filed and seeks to...
-
SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- SelectQuote Inc. (NYSE: SLQT) faced renewed investor pressure on Monday, May 12, 2025, as its shares tumbled another 12% following the release of...
-
SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- On May 15, 2025, investors in Coinbase Global, Inc. (NASDAQ: COIN) saw the price of their shares slide about 7% after the company announced that it...
-
SAN FRANCISCO, June 11, 2025 (GLOBE NEWSWIRE) -- A year ago, Bay Area biotech firm Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) was riding high on the promise of its newly approved cell therapy,...